A proprietary blend does not automatically need a new GRAS conclusion simply because it contains multiple ingredients.
Existing GRAS conclusions or other regulatory authorizations may be sufficient when every component is lawful for the proposed food use, remains within its supported conditions of use, and is combined without creating new safety concerns.
One GRAS conclusion can potentially cover an entire proprietary blend when the blend is marketed as a standardized ingredient and the assessment clearly defines its composition, manufacturing process, specifications, intended uses, exposure and safety.
A new blend-level GRAS assessment may be appropriate when:
- One or more components lack an applicable legal basis for use
- Processing results in a new substance or reaction product with a different identity or composition from the starting materials
- The combination is expected to materially alter exposure, absorption, metabolism, or toxicity in a way that raises a new safety concern
- The combination may result in additive, synergistic, or other interactions that raises a new safety concern
- Proposed use levels or exposure exceed the levels supported by the applicable GRAS conclusion or other legal basis for use
- The proposed use falls outside the food categories, target populations, or other conditions of use supported by the existing safety conclusion
Separate new GRAS dossiers are not always required for every ingredient. However, every component must be lawful for its intended use, and the safety of the complete blend must be adequately supported.
Developing a proprietary blend can create an important regulatory question: if every component is already Generally Recognized as Safe (GRAS), can the ingredients be combined under one existing GRAS conclusion, or does the blend require a new safety assessment?
The answer depends on more than the number of ingredients in the formulation.
A mixture of lawful food ingredients does not automatically require a new GRAS conclusion simply because the ingredients are combined. However, existing GRAS conclusions may not be sufficient when the blend creates a new substance, changes how its components behave, increases consumer exposure, or falls outside the previously supported conditions of use.
The key is understanding exactly what is being sold and how it will be used.
GRAS is not a general certification stating that an ingredient is safe for every product, dose, food category, manufacturing process, or population.
Instead, a GRAS conclusion applies to the use of a particular substance under specified conditions. Those conditions may include:
Under the GRAS standard, the safety of the substance under its intended conditions of use must be generally recognized among qualified experts by scientific procedures or, for substances used in food before 1958, through experience based on common use in food. For a GRAS conclusion based on scientific procedures, the safety information must be publicly available and generally accepted by qualified experts in the relevant scientific community.
Therefore, the question is not simply whether each ingredient has previously been described as GRAS. The more important question is whether the exact ingredients, uses, levels, and product characteristics remain within the scope of the applicable regulatory and safety conclusions.
In many cases, yes.
A finished food or beverage can contain several ingredients that each have an appropriate legal basis for their intended use. The manufacturer does not ordinarily need to prepare a new GRAS conclusion for every finished-product recipe.
For example, a beverage might contain:
Combining these ingredients does not necessarily create a new food substance. It may simply create a conventional formulation containing several independently lawful ingredients.
A separate blend-level GRAS conclusion may not be necessary when:
Even when a new GRAS conclusion is not required, the manufacturer should document the regulatory basis for every component and assess the safety of the finished formulation.
Simply stating that “all ingredients are GRAS” is not a complete regulatory assessment.
A single GRAS conclusion can potentially cover a proprietary blend when the blend itself is clearly defined and evaluated as the substance intended to be added to food.
In this situation, the subject of the GRAS conclusion is not necessarily each component considered separately. The GRAS conclusion may instead address the blend as a defined substance.
For example, a company might manufacture a proprietary hydration ingredient containing specific proportions of sodium, potassium and magnesium salts. One GRAS conclusion could potentially address the complete blend if the dossier adequately defines and supports:
This approach is most defensible when the product is consistently manufactured and marketed as one standardized commercial ingredient.
However, one GRAS conclusion for a blend is not a blank cheque for future formulations. Changes to the composition, ingredient ratios, manufacturing process, specifications or intended uses may affect whether the original conclusion remains applicable.
Not necessarily in the form of a separate GRAS dossier or FDA GRAS notice.
Every substance intentionally added to conventional food must have a lawful basis for its intended use. That basis might be:
Therefore, a component does not always need its own newly prepared GRAS conclusion. It does, however, need an appropriate regulatory basis for the way it is used in the blend and ultimately in food.
A company could support a proprietary blend through one comprehensive GRAS evaluation that establishes the safety of the blend and addresses all of its components. Alternatively, the company might rely on existing regulatory authorizations, applicable regulations, or GRAS conclusions for individual components while conducting a focused assessment of the combined formulation.
The appropriate regulatory approach depends on whether the product is merely a physical mixture or a distinct ingredient with its own identity and safety questions.
Existing conclusions may be sufficient when the blend is a straightforward physical mixture (provided the combination does not create additive effects or changes exposure).
Consider a powdered electrolyte blend made by dry-mixing established forms of sodium chloride, potassium citrate and magnesium citrate.
A new blend-level GRAS conclusion may not be needed if:
In this case, the company may be able to prepare a regulatory assessment documenting why the blend remains within existing legal basis rather than conducting a completely new GRAS process.
This assessment should still consider cumulative exposure. For example, potassium exposure cannot be evaluated only from the amount of potassium citrate contributed by one product if consumers may also receive potassium from other foods, beverages and supplements.
A proprietary blend may require a new or more comprehensive GRAS evaluation when it is effectively a distinct food substance rather than a simple combination of existing ingredients.
1. The manufacturing process creates a new substance
Mixing ingredients is different from reacting, fermenting, chelating or otherwise transforming them.
A process may create:
In these situations, the regulatory status of the starting materials does not automatically establish the status of the resulting substance.
For example, the fact that magnesium and glycine each have lawful food uses would not, by itself, establish that a particular magnesium glycinate ingredient is GRAS for every proposed use. The resulting ingredient must be properly identified and supported based on its manufacturing process, composition, specifications, exposure and safety evidence.
2. The combination change materially affects systemic exposure or safety
A formulation may increase the absorption or systemic exposure of one or more components.
This can occur through:
An ingredient that has been shown to be safe at a particular level of systemic exposure may require additional evaluation when delivered in a way that significantly increases bioavailability and systemic exposure.
3. The blend creates new physiological effects
Ingredients that affect the same biological system may have additive, synergistic or otherwise interacting effects.
This can be relevant when combining substances that influence:
The presence of several individually supported ingredients does not eliminate the need to examine whether their effects could accumulate when consumed together.
4. Proposed use levels exceed existing support
An ingredient may have a GRAS basis at a particular maximum use level but not at the higher level proposed for a concentrated powder, shot, functional beverage or other formulation.
A new assessment may be needed when the formulation changes:
Diluting a substance into a blend does not necessarily resolve this issue. Safety depends on the amount consumers are expected to ingest, not merely the percentage printed in the blend specification.
5. The product targets a different population
A safety conclusion based on use by the general adult population may not support use in products intended for:
When a product is intended for a more sensitive group, the scientific evidence and exposure assessment should be appropriate for that population.
6. The ingredient identity has changed
An existing conclusion may address a specific source, strain, salt, extraction method, particle size, purity or chemical form.
It may not cover:
Similarity in the ingredient name is not enough. The substance covered by the safety conclusion must be sufficiently representative of the commercial ingredient.
An important distinction is whether the company is selling:
A finished food manufacturer generally establishes an appropriate legal basis for each ingredient and evaluates the safety of the completed formulation under its intended conditions of use. The manufacturer does not typically seek a separate GRAS conclusion for every flavour or product variation, provided that each ingredient has an appropriate legal basis and the final formulation remains within the applicable conditions of use and is adequately supported for safety.
A supplier marketing a proprietary blend as a standalone ingredient may have a stronger reason to establish a blend-specific GRAS conclusion. This can help clearly define the blend’s identity, permitted uses, maximum levels and safety basis for downstream customers.
A blend-level conclusion may also provide commercial value by giving customers a defined regulatory package for the branded ingredient.
However, the conclusion will only cover the specific composition and conditions evaluated. It does not automatically extend to every customer application or every future variation of the blend.
This is not the best starting test.
Under the Federal Food, Drug, and Cosmetic Act, a food containing an unsafe food additive is generally adulterated under the relevant statutory provision. But adulteration is the potential regulatory consequence; it does not explain how a company should determine whether a blend has an adequate legal and safety basis.
A more useful series of questions is:
The manufacturer should be able to answer and document each of these questions before concluding that the formulation is adequately supported.
Companies evaluating a proprietary blend can begin with the following steps.
Step 1: Define the product
Determine whether the product is:
This establishes what substance must be assessed.
Step 2: Map the regulatory basis for every component
For each component, document:
Do not rely only on supplier statements such as “GRAS compliant” without confirming what uses are actually supported.
Step 3: Compare the proposed conditions of use
Compare the new formulation with the conditions supported by the existing regulatory basis.
Consider:
A change in one or more of these factors could result in a use that was not previously evaluated or adequately supported.
Step 4: Assess the blend as consumed
Evaluate whether combining the ingredients affects:
The depth of this assessment should reflect the complexity and risk profile of the blend.
Step 5: Identify scientific gaps
Determine whether the available public evidence supports the exact substance and intended use.
Depending on the gaps, additional work may include:
New testing is not automatically required for every blend. The need depends on the quality, relevance, and completeness of the existing evidence.
Step 6: Select the regulatory strategy
Possible outcomes include:
FDA does not formally “approve” a substance through the GRAS notification program. Following its review, FDA may respond that it has no questions regarding the notifier’s conclusion that the substance is GRAS under the intended conditions of use. The responsibility for ensuring that the substance is safe and lawfully used remains with the responsible company and other applicable parties in the supply chain.
Assuming “GRAS” applies to every use
A substance may be supported in baked goods at one level but not in beverages at a much higher level.
Treating the GRAS inventory as a complete positive list
Not every GRAS conclusion is submitted to FDA through the GRAS Notice program, and the presence or absence of a substance in FDA’s GRAS Notice inventory does not establish whether the substance is GRAS or otherwise lawful for a particular use. Relying only on the individual ingredients
This overlooks interactions, cumulative exposure and changes introduced by processing.
Treating every formula change as a new GRAS project
Minor formulation changes may be supportable through an amendment, bridging assessment or internal memorandum rather than a completely new dossier.
Calling a transformed substance a “blend”
A product created through reaction, chelation or fermentation may be a distinct substance even when it begins with familiar ingredients.
Confusing GRAS with dietary supplement requirements
GRAS is principally relevant to substances intentionally added to conventional food. Dietary ingredients used only in dietary supplements are subject to a different regulatory framework, including the New Dietary Ingredient provisions where applicable. A dietary ingredient may still need a GRAS basis when it is intended for use in conventional food.
A proprietary blend does not automatically need a separate GRAS conclusion simply because it contains multiple ingredients.
Existing legal basis may be sufficient when all components are lawful for the proposed use, remain within their supported conditions, and are combined without creating new safety concerns.
One GRAS conclusion can potentially cover a proprietary blend when the blend itself is clearly defined as the substance being evaluated and its composition, manufacturing process, specifications, intended uses, exposure, and safety are adequately supported.
Separate new GRAS dossiers are not necessarily required for every component, but every component must have a lawful basis for its intended use.
A blend-level assessment becomes more important when manufacturing creates a distinct substance, bioavailability changes, effects may be additive or synergistic, exposure increases, or the product is intended for a new population or food category.
Ultimately, the correct strategy depends on the identity of the commercial ingredient, how it is manufactured and the conditions under which consumers will be exposed to it.
dicentra helps ingredient manufacturers, formulators and food companies determine whether a proprietary blend can rely on existing legal basis or requires a new GRAS conclusion.
Our team can support:
Whether your product is a straightforward mixture, a branded electrolyte system, a botanical blend, a mineral complex or a novel formulation technology, an early assessment can help identify the most efficient and defensible route to the U.S. market.
Contact dicentra to discuss the regulatory strategy for your proprietary ingredient blend.